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Expression of MHC of classes I and II antigens is 
one of the major characteristics of lymphocytes and 
tumor cells. As a rule, different alterations of the genes 
coding these antigens are leading to the disturbance 
of their functioning or significantly affect immuno-
logic response. That’s explaining why the patterns of 
genotype of lymphocytes and tumor cells, in particular 
expression of MHC antigens plays significant role in 
recognition of tumor antigens with the following lysis of 
tumor cells. Such statement is proved in a number of 
studies, at the first hand - in classic works of R. Zinker-
nagel [1, 2] where it is reported that immunological 
response occurs only upon expression of the same 
MHC alleles on lymphocytes and tumor cells.  
In the last years a number of publications are 
arguing that efficacy of immunotherapy depends on 
expression of the alleles of MHC antigens that repre-
sent discrete peptides of tumor cells in each concrete 
case. For example, it was shown that such peptides 
of prostate cancer cells are represented by HLA-A24, 
and particularly these molecules are inducing specific 
immune response if tumor cells express HLA-A24 [3]. 
Similar data were received in the research of specific 
response of T-lymphocytes of patients with gastric 
cancer; these lymphocytes are lyzing tumor cells if 
both types of the cells express HLA-A2 or HLA-A24 
antigens [4].
An important role in interactions between lympho-
cytes and tumor cells belongs to the patterns of their 
proteome composed from a variety of receptor and 
antigens, each of which is controlled by respective 
genes. Disturbance of their functions results in pro-
teome alterations.
Realization of cytotoxic action depends on expres-
sion of MHC classes I and II antigens and patterns of 
proteome; however, the question — at what degree 
such dependence affects the efficacy of cytotoxic 
action of lymphokin-activated cells (LAK) — requires 
further examination. At the same time, adoptive immu-
notherapy of cancer with the use of LAK is known to oc-
cupy one of the central places in cancer imunotherapy. 
Presently the use of IL-2 for activation of lymphocytes 
is the mostly widely used approach [5, 6].
Since the first report on LAK-phenomenon, it became 
the subject of active studies (phenotypic characteristics 
of LAK cells, intensity of their killer activity, patterns of 
action of LAK isolated from different subpopulations of 
cells, research of LAK migration in the body). However, 
the results are contradictory, possibly due to application 
of different approaches for generation of LAK (doses of 
IL-2, terms of cultivation, the sourse of lymphocytes, 
their phenotype etc) [7–9].
As it is mentioned above, the role of patterns of 
LAK phenotype and tumor cells in their interaction 
remained poorly studied yet; but single reports are 
demonstrating that therapeutic effect of immuno-
therapy with the use of IL-2-activated LAK depends 
on phenotype of these cells, too [10]. However, in one 
cases expression of MHC antigens has been studied 
only on tumor cells, in other cases — only on LAK. So, 
it looks reasonable to study the role of expression of 
MHC antigens and other components of proteome by 
tumor cells and LAK for their interaction. 
The first stages of interaction between LAK and 
target cells is the expression of adhesion molecules 
CD11a/CD18, CD54; in some publications it has been 
reported that the expression of mentioned proteins 
and MHC class I antigens occurs simultaneously 
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[11, 12]. The role of expression of ICAM-1 (CD54), in 
particular on tumor cells for interaction with LAK has 
been shown also by other studies [13], that demon-
strated that application of retinoid acid — compound 
increasing expression of the gene controlling ICAM-1 
expression in tumor cells — resulted in elevation of 
sensitivity of tumor cells to action of LAK. Melanoma 
cells expressing MHC antigens became more sensitive 
to lyzis with LAK [14]; transfection of human ovarian 
cancer cells SKOV3 with IL-2 gene leads to significantly 
increased expression of HLA-ABC, HLA-DR, HLA-DQ 
molecules [15]. 
The role of MHC antigens expression on tumor 
cells and their positive or negative regulation may sig-
nificantly depend on phenotype of cells, that possess 
cytotoxicity. In particular, it was shown that treatment 
of tumor cells with INFγ may lead to suppression of 
action of LAK obtained from natural killer cells; ex-
pression of such MHC class I molecules as 1a and 
1b suppresses cytotoxicity, and such inhibition may 
be abolished by treatment with antibodies against 
mentioned antigens [16].
The present work, is aimed on the study of MHC 
antigens expression on tumor cells as well on LAK 
in parallel with detection of the expression of some 
receptors, that may play role in LAK-dependent lysis. 
There were two main tasks: 1) to evaluate possible 
relation between expression of MHC class I and II 
antigens on lymphocytes and tumor cells (soft tissue 
sarcomas and skin melanomas) and antitumor action 
of non-activated and IL-2-activated lymphocytes; 
2) to study the role of expression of some receptors 
for realization of antitumor action of LAK.
mAteriAls And methods
In the work tumor cells and PBL of 20 patients 
with soft tissue sarcoma (liposarcoma (n = 2), rhab-
domyosarcoma (n = 2), fibrosarcoma (n = 3), syno-
vial sarcoma (n = 6), inclassified sarcoma, (n = 2), 
angyoleiomyosarcoma (n = 2), malignant mesinchy-
moma, neurosarcoma (n = 1), angyosarcoma (n = 1), 
malignant giant cell sarcoma (n = 1)) and 25 patients 
with melanoma cured in the Institute of Oncology, AMS 
of Ukraine (Kyiv, Ukraine) were used. The patients 
were 15–79 years old; from 20 cases with soft tissue 
sarcoma, 8 patients were at the II stage of the disease, 
10 — at III stage, 2 — at IV stage; from 25 melanoma 
cases, 15 patients were at І, ІІ stages, 10 — at ІІІ and 
IV stages.
PBL were isolated from heparinized blood by 
centrifugation in Ficoll-urograffin gradient (ρ = 1.077). 
Isolated tumor cells were obtained by enzymatic dis-
aggregation of tumor tissue with 2 mg/ml collagenase 
(Sigma, USA) and 1 ng/ml DNAse (Sigma, USA) for 
40 min at 37 ˚С. 
Expression of MHC classes I and II antigens, adhe-
sion molecule CD54, transferrine CD71, interleukine-2, 
CD25, CD54, CD56, CD11b, antigen of proliferation 
Кі-67, nuclear antigen of proliferation on tumor cells 
and lymphocytes from patients was studied by the 
method of indirect fluorescence using respective 
monoclonal antibodies (MoAbs) (Medbiospecter, Rus-
sia; DacoCytomation, Denmark; MoAb IPO-38, IEPOR 
NAS, Kiev, Ukraine). Antitumor activity of lymphocytes 
was studied by their co-cultivation with tumor cells in 
diffusional chambers [17] with the following morpho-
logical examination of the samples.
results And discussion
Comparative evaluation of antitumor action of acti-
vated (LAK) and non-activated lymphocytes of the pa-
tients with soft tissue sarcoma  has shown that PBL are 
characterized by expression of high level MHC class 
I antigens and low level — of class II, whilst IL-2 does 
not alter significantly their expression levels. Upon 
influence of IL-2, expression of CD25 varied in a wide 
range; that fact may be explained by individual patterns 
of lymphocytes of these patients (Table 1). 
On the base of the results of studied interactions 
between tumor cells and PBL, the patients were 
grouped as follow: 1) patients possessing PBL and LAK 
with marked antitumor activity, 2) patients possessing 
PBL and LAK without antitumor activity.
Table 1. Expression of MHC class І and ІІ by activated (LAK) and not activated 
(PBL) lymphocytes and tumor cells of patients with soft tissue sarcoma
Marker Antitumor activity 
(% cells) + –PBL LAK TC PBL LAK TC
HLA-ABC 78.7 ± 7.3 80.4 ± 3.0 28.5 ± 6.8 71.6 ± 7.5 81.2 ± 3.2 12.8 ± 3.8
HLA-DR 17.4 ± 2.4 19.9 ± 2.2 13.9 ± 4.4 14.4 ± 2.5 16.7 ± 2.8 13.2 ± 4.5
Notes: TC – tumor cells, PBL — peripheral blood lymphocytes, LAK – IL-2 
activated lymphocytes.
The study of antitumor action of PBL from the 
patients with melanoma has demonstrated that the 
highest effect was observed against tumor cells ex-
pressing the highest level of MHC of class І antigens 
(Table 2).
Table 2. Expression of MHC class І and ІІ by lymphocytes and tumor cells 
of patients with melanoma 
Markers Antitumor activity 
(% cells) + –PBL TC PBL TC
HLA-ABC 75.2 ± 1.3 23.8 ± 2.2 85.3 ± 2.1 15.2 ± 2.1
HLA-DR 23.0 ± 2.7 10.6 ± 4.2 13.5 ± 3.3 12.3 ± 3.7
Notes: TC – tumor cells, PBL — peripheral blood lymphocytes.
So, one may conclude that the most marked anti-
tumor action of lymphocytes of the patients with soft 
tissue sarcoma or melanoma is achieved against tumor 
cells expressing MHC class І antigens.
Next, we have studied the expression of CD25, 
CD54, CD71, Ki-67 on tumor cells of various types 
(different soft tissue sarcoma, melanoma) and on 
non-acticvated and activated lymphocytes. First of 
all, we have revealed that expression of the markers 
on tumor cells and lymphocytes is characterized by 
pronounced individual patterns. 
The data have demonstrated the absence of cor-
relation between the level of antitumor activity and 
expression of mentioned proteins (Table 3) that may 
be possibly explained by  different tumor types studied 
(fibrosarcoma, rhabdomyosarcoma, liposarcoma etc). 
It is known that expression of the markers may differ 
even between the cell lines originated from the same 
tumor [18]. 
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Table 3. Expression of CD25, CD54, CD71, Ki-67 by activated (LAK) and not ac-
tivated (PBL) lymphocytes and tumor cells of patients with soft tissue sarcoma 
Mar-
kers
(% 
cells)
Antitumor activity
+ –
PBL LAC TC PBL LAC TC
CD25 9.1 ± 1.7 15.6 ± 2.9 12.6 ± 2.4 14.4 ± 2.6 21.6 ± 3.7 8.6 ± 2.7
CD54 6.8 ± 0.9 6.5 ± 1.2 18.3 ± 7.8 7.2 ± 1.6 7.6 ± 1.3 11.3 ± 1.1
CD71 5.6 ± 0.7 6.7 ± 1.6 27.6 ± 2.6 7.4 ± 0.7 10 ± 1.6 31.5 ± 3.7
Ki-67 12.5 ± 5.4 22.3 ± 11.8 29.3 ± 8.5 12.4 ± 1.9 17.4 ± 4.5 23.3 ± 3.3
Notes: TC – tumor cells, PBL — peripheral blood lymphocytes, LAK – IL-2 
activated lymphocytes.
The study of expression patterns of CD25, CD54, 
PCNA by melanoma cells and CD25, CD56, CD11b 
by lymphocytes has shown that the highest antitumor 
action of lymphocytes is associated with the highest 
expression of CD11b. In some cases upon the absence 
of antitumor activity, the tendency for elevated CD25 
expression on tumor cells has been observed (Table 4). 
These data point on importance of CD11b expression 
in realization of antitumor action of lymphocytes. 
Table 4. Antitumor action of tumor cells and peripheral blood lymphocytes 
of patients with melanoma
Antitumor action (AA) Tumor cells, % cells PBL, % cells
PCNA CD25 CD54 CD25 CD56 CD11b
Possessing AA 19.7 ± 
4.8
12.4 ± 
3.9
25.5 ± 
10.8
9.5 ± 
1.4
10.6 ± 
2.1
18.5 ± 
3.4*
Not possessing AA 16.9 ± 
4.6
15.0 ± 
2.9
33.4 ± 
8.7
8.1 ± 
2.4
8.8 ± 
1.4
8.4 ± 
1.2*
Notes: *the difference between indexes for the patients of I and II groups 
is statistically significant (р < 0.05).
Analyzing the obtained results, one may conclude 
that for antitumor action of PBL and LAK toward sar-
coma and melanoma cells, expression of MHC class I 
antigens is required not only on lymphocytes, but also 
on tumor cells. So, one may suppose that in theses 
cases the central role for antitumor action belongs for 
cytotoxic T-lymphocytes that react on tumor antigens 
presented by MHC class I antigens [19, 20]. Such state-
ment is in agreement with the data of literature eviden-
cing that altered expression of class I HLA molecules 
on cells leads to significantly decreased recognition 
of them by CTL [21]. It’s interesting to note also that 
certain epitopes of HLA-А expressed on tumor cells of 
different genesis are making them more sensitive for 
immunotherapy [22].
The obtained results are evidencing that PBL 
and LAK of the patients with soft tissue sarcoma and 
melanoma are showing the highest antitumor activity 
toward tumor cells with elevated expression level of 
MHC class I antigens. Expression levels of CD25, CD71, 
Ki-67, CD54, CD56, CD11b, PCNA (detected by MoAb 
IPO-38) are characterized by significant individual 
variations that are possibly caused by disregulation of 
their expression on the level of genome. Along with the 
absence of statistically significant correlation between 
expression of different markers and antitumor action of 
lymphocytes and LAK toward sarcoma cells, the strict 
correlation between CD11b expression on lymphocytes 
of patients with melanoma and their antitumor action 
has been revealed. According to our data, the respective 
expression level of MHC class I antigens is promoting 
the sensitivity of tumor cells to action of LAK.
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ПротивооПухолевое действие 
лимфокинактивированных лимфоцитов больных 
саркомами мягких тканей и меланомой в зависимости 
от эксПрессии антигенов І и ІІ класса главного 
комПлекса гистосовместимости
Цель: изучить экспрессию антигенов І и ІІ класса главного комплекса гистосовместимости (ГКГ) на лимфоцитах и опухолевых 
клетках (саркомы мягких тканей и меланома кожи) и противоопухолевое действие лимфоцитов, активированных и 
неактивированных ИЛ-2 параллельно с экспрессией некоторых рецепторов, характеризующих протеом. Материалы и методы: 
культивирование эксплантатов опухоли и аутологичных лимфоцитов в диффузионных камерах с дальнейшим изучением 
противоопухолевого действия лимфоцитов на основании морфологических особенностей роста эксплантатов. Экспрессию 
антигенов CD25, CD71, Ki-67, CD54, CD56, CD11b, ядерного антигена пролиферирующих клеток (ИПО-38) определяли 
методом непрямой флуоресценции с помощью соответствующих моноклональных антител. Результаты: наиболее выраженное 
противоопухолевое действие лимфоцитов как больных саркомами мягких тканей, так и меланомой проявляется по отношению 
к тем опухолевым клеткам, которые экспрессируют антигены I класса ГКГ. Установлено, что значение экспрессии указанных 
структур для противоопухолевого действия зависит от биологических особенностей опухоли: зависимости между уровнем 
противоопухолевой активности и экспрессией изученных рецепторов клетками больных саркомой не выявлено. В то же время 
наиболее выраженное противоопухолевое действие лимфоцитов больных меланомой сочеталось с высоким уровнем экспрессии ими 
CD11b. Выводы: установлена прямая зависимость чувствительности опухолевых клеток к действию лимфокинактивированных 
клеток от уровня экспрессии антигенов ГКГ I класса на клетках как меланомы, так и сарком. 
Ключевые слова: антигены І и ІІ классов ГКГ, ЛАК, саркоми мягких тканей, меланома.
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